Thames Valley Dedicated Research Centre
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Investigator, Madrigal
MAESTRO-NASH, NCT03900429 / 2018-004012-22: A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Active, not recruiting
3
1759
Europe, Canada, US, RoW
MGL-3196, Resmetirom, Placebo, Liver Biopsy
Madrigal Pharmaceuticals, Inc.
NASH - Nonalcoholic Steatohepatitis
01/28
01/28
NCT04951219: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Recruiting
3
1000
US
Resmetirom, MGL-3196
Madrigal Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease
03/26
04/26
NCT04643795: Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Completed
1
87
US
MGL-3196
Madrigal Pharmaceuticals, Inc.
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
08/21
08/21

Download Options